• First contact – how big things come from small steps…

  • Nov 10 2024
  • Length: 35 mins
  • Podcast

First contact – how big things come from small steps…

  • Summary

  • The special mini-series of Cancer Research Matters takes a deep dive into all things science entrepreneurship.


    This first episode asks: why should entrepreneurship and translation interest researchers from an academic background? Isn’t this a tricky thing to navigate? What support is available? What kinds of research can be translated and what should researchers do if they think their work could lead to an intervention. It’s all in here – so get stuck in.


    Appearing in this episode:


    Simon Boulton

    Principal Group Leader, The Francis Crick Institute

    Co-founder & VP Science Strategy, Artios Pharma Ltd

    Chief Translation Advisor, Cancer Research UK

    Simon’s lab has discovered new DNA repair genes and provided novel insights into cancer. In 2016, Simon helped to establish Artios Pharma Ltd where he functions as Vice President of Science Strategy alongside his academic roles at the Francis Crick Institute and Cancer Research UK. Artios are developing new treatments that target DNA repair pathway vulnerabilities to selectively kill cancer cells. Simon is also Chief Translation Advisor at Cancer Research UK, with the remit to guide translation and commercialisation of novel cancer therapeutics.


    Tony Hickson

    Chief business officer, Cancer Research UK and Cancer Research Horizons

    Tony leads the Commercial Partnerships team responsible for the commercialisation of IP from Cancer Research UK-funded projects, new start-up creation, licences and corporate alliances.


    Faith Howard

    Postdoctoral Research Associate, University of Sheffield

    Co-Founder at NANOncolytics

    Faith’s research interests are focused on delivery of therapeutics to disseminated tumours. This includes nanoenabled formulations and the development of appropriate models for studying immunotherapies. She is cofounder of NANOncolytics, a company developing nanoparticle technology to provide a less invasive strategy for treating inaccessible and aggressive tumours.


    Tommy Rennison

    Regional Translation Lead, Cancer Research Horizons

    Tommy is responsible for sourcing and evaluating potential new projects for Cancer Research Horizons.


    Phil Berry

    Translation Executive at Cancer Research Horizons

    Phil is responsible for sourcing and evaluating potential new projects for Cancer Research Horizons.


    Useful links

    Cancer Research Horizons

    Cancer Research Horizons entrepreneurial training

    The Venture Builder Incubator

    ICURe Programme


    Hosted on Acast. See acast.com/privacy for more information.

    Show More Show Less
activate_Holiday_promo_in_buybox_DT_T2

What listeners say about First contact – how big things come from small steps…

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.